PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials-Reference-Cited by-同舟云学术

PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials

Published:2018-05 Issue: Volume:153 Page:70-77
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Malcolm Bruce Albert,Aerts Caroline Anne,Dubois Kristof Johan,Geurts Frederik Joris,Marien Kris,Rusch Sarah,Van Dijck Alex Henri,Verloes Rene,Vingerhoets Johan

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference35 articles.

1. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans;Caskey;J. Exp. Med.,2011

2. Rhinovirus infection associated with serious lower respiratory illness in patients with bronchopulmonary dysplasia;Chidekel;Pediatr. Infect. Dis. J.,1997

3. The presence of fever in adults with influenza and other viral respiratory infections;Chughtai;Epidemiol. Infect.,2017

4. Degradation of poly(inosinic acid) - poly(cytidylic acid) [(I)n - (C)n] by human plasma;de Clercq;Eur. J. Biochem.,1979

5. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV);DeVincenzo;Antivir. Res.,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral Approaches against Influenza Virus;Clinical Microbiology Reviews;2023-03-23

2. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice;Scientific Reports;2023-03-21

3. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice;2022-12-07

4. A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease;International Journal of Molecular Sciences;2022-02-06

5. A novel Pan-viral prophylaxis strategy using vaccine adjuvant CAF09b protects against influenza virus infection;2021-10-21